New Oral Semaglutide Formulation Completes Phase 1 Pharmacokinetic Study

Semaglutide, a GLP-1 receptor agonist (a class of drugs that mimic a natural hormone to regulate blood sugar and appetite), is a cornerstone treatment for type 2 diabetes and obesity. While an oral formulation (Rybelsus) already exists, pharmaceutical companies continuously develop new compositions to improve absorption, bioavailability, or patient convenience. This Phase 1 study by Novo Nordisk A/S aimed to investigate how different dosing conditions affect the blood levels (pharmacokinetics) of a novel oral semaglutide formulation in healthy individuals.

While specific quantitative pharmacokinetic results are pending publication, this Phase 1 study successfully completed, enrolling 121 healthy participants. The investigation aimed to characterize key pharmacokinetic parameters such as Cmax (maximum concentration), Tmax (time to Cmax), and AUC (area under the curve) for oral semaglutide D under different dosing conditions. Participants received two distinct oral semaglutide D dosing regimens, each administered for 5 days, totaling 10 days of intervention. The successful completion of this study means that critical data on the absorption and blood levels of this new oral semaglutide formulation under varying conditions has been gathered from 121 individuals, providing foundational insights for its future development.